- Record: found
- Abstract: found
- Article: not found
Sunitinib malate for the treatment of pancreatic neuroendocrine tumors.
Eric Raymond
1 ,
Laetitia Dahan ,
Jean-Luc Raoul ,
Yung-Jue Bang ,
Ivan Borbath ,
Catherine Lombard-Bohas ,
Juan Valle ,
Peter Metrakos ,
Denis Smith ,
Aaron Vinik ,
Jen-Shi Chen ,
Dieter Hörsch ,
Pascal Hammel ,
Bertram Wiedenmann ,
Eric Van Cutsem ,
Shem Patyna ,
Dongrui Ray Lu ,
Carolyn Blanckmeister ,
Richard Chao ,
Philippe Ruszniewski
Feb 10 2011
Read this article at
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
The multitargeted tyrosine kinase inhibitor sunitinib has shown activity against pancreatic neuroendocrine tumors in preclinical models and phase 1 and 2 trials.